{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:13:16Z","timestamp":1789668796155,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rpth.2026.106929","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:08:36Z","timestamp":1787814516000},"page":"106929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinct changes in plasma protein profiles of cancer patients receiving immune checkpoint inhibitors versus chemotherapy: implications for thrombosis risk and adverse outcomes"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9502-2434","authenticated-orcid":false,"given":"Eleonora","family":"Camilleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Vladic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Englisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Fuereder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Renee","family":"Ruhaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne C.","family":"Cannegieter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.M.","family":"van Vlijmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederikus A.","family":"Klok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9717","authenticated-orcid":false,"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106929_bib1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer therapy\u2013associated thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2026.106929_bib2","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106929_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010761","article-title":"Immune checkpoint inhibitor-associated risk for venous thromboembolism: a comprehensive analysis","volume":"13","author":"Sussman","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.rpth.2026.106929_bib4","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1111\/jth.15880","article-title":"Hemostasis and cancer: impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer","volume":"20","author":"Moik","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106929_bib5","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3892\/mco.2015.584","article-title":"Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients","volume":"3","author":"Wang","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106929_bib6","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/j.1538-7836.2007.02788.x","article-title":"Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity","volume":"5","author":"Lechner","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106929_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.rpth.2026.106929_bib8","article-title":"Risk assessment and prevention of cancer-associated venous thromboembolism in ambulatory patients with solid malignancies","volume":"9","author":"Vladic","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106929_bib9","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-20-2000","article-title":"Inflammation and apolipoproteins are potential biomarkers for stratification of cutaneous melanoma patients for immunotherapy and targeted therapy","volume":"81","author":"Karlsson","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.rpth.2026.106929_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1364473","article-title":"Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy","volume":"15","author":"Bar","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.rpth.2026.106929_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/qub2.34","article-title":"Plasma proteome profiling reveals biomarkers of chemotherapy resistance in patients with advanced colorectal cancer","volume":"12","author":"Yang","year":"2024","journal-title":"Quant Biol"},{"key":"10.1016\/j.rpth.2026.106929_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104130","article-title":"The Vienna CATScore for predicting cancer-associated venous thromboembolism: an external validation across multiple time points","volume":"10","author":"Englisch","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.rpth.2026.106929_bib13","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood.2024025362","article-title":"Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study","volume":"144","author":"Englisch","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106929_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.rpth.2026.106929_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.rpth.2026.106929_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz0274","article-title":"The human secretome","volume":"12","author":"Uhl\u00e9n","year":"2019","journal-title":"Sci Signal"},{"key":"10.1016\/j.rpth.2026.106929_bib17","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/jth.15623","article-title":"Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower-leg injury or knee arthroscopy","volume":"20","author":"Mohammed","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106929_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103018","article-title":"Quantitative targeted proteomics for occult cancer screening in patients with unprovoked venous thromboembolism: results from the prospective PLATO-VTE study","volume":"9","author":"Guman","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106929_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bjh.70278","article-title":"Plasma proteomic profiles of patients during oral anti-coagulant treatment with vitamin K antagonists","volume":"208","author":"Camilleri","year":"2026","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106929_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2026.109612","article-title":"Absolute quantitative proteomics identifies patterns of plasma proteins associated with venous thromboembolism in patients with colorectal cancer","volume":"259","author":"Buijs","year":"2026","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106929_bib44","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgag120","article-title":"Distinct plasma protein profiles after long-term remission of Cushing\u2019s disease","author":"van der Vliet","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.rpth.2026.106929_bib21","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106929_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106929_bib23","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rpth.2026.106929_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"2018","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.rpth.2026.106929_bib25","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.21873\/anticanres.16920","article-title":"Immune checkpoint inhibitor therapy for patients with non-small cell lung cancer ineligible for platinum doublet chemotherapy","volume":"44","author":"Inomata","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.rpth.2026.106929_bib26","article-title":"First-line immune checkpoint inhibitors in low programmed death-ligand 1-expressing population","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.rpth.2026.106929_bib27","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.rpth.2026.106929_bib28","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.rpth.2026.106929_bib29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.rpth.2026.106929_bib30","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-16-0224","article-title":"Dual faces of IFN\u03b3 in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity","volume":"22","author":"Mandai","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.rpth.2026.106929_bib31","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","article-title":"Non-small-cell lung cancer","volume":"378","author":"Goldstraw","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.106929_bib32","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/cancers12061619","article-title":"Systemic inflammation and activation of haemostasis predict poor prognosis and response to chemotherapy in patients with advanced lung cancer","volume":"12","author":"Moik","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.rpth.2026.106929_bib33","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jth.12075","article-title":"Coagulation and cancer: biological and clinical aspects","volume":"11","author":"Falanga","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106929_bib34","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.1002\/cam4.5918","article-title":"Distinct circulating cytokine\/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non-small cell lung cancer","volume":"12","author":"Hu","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.rpth.2026.106929_bib35","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.3390\/cancers16091759","article-title":"Kinetics of IFN\u03b3-induced cytokines and development of immune-related adverse events in patients receiving PD-(L)1 inhibitors","volume":"16","author":"Alserawan","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.rpth.2026.106929_bib36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.thromres.2011.11.040","article-title":"Factor XIII, clot structure, thrombosis","volume":"129","author":"Bagoly","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106929_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.719085","article-title":"Coagulation factor XIII subunit A is a biomarker for curative effects and prognosis in malignant solid tumors, especially non-small cell lung cancer","volume":"11","author":"Luo","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.rpth.2026.106929_bib38","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3349\/ymj.2013.54.6.1394","article-title":"Relationships of coagulation factor XIII activity with cell-type and stage of non-small cell lung cancer","volume":"54","author":"Lee","year":"2013","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.rpth.2026.106929_bib39","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00277-023-05261-y","article-title":"Reduced plasma coagulation factor XIII in patients with acute leukemia in remission during consolidation chemotherapy cycles","volume":"102","author":"Lv","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rpth.2026.106929_bib40","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s00125-012-2598-x","article-title":"Adiponectin: mechanistic insights and clinical implications","volume":"55","author":"Turer","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.rpth.2026.106929_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.848394","article-title":"Metabolic reprogramming in adipose tissue during cancer cachexia","volume":"12","author":"Weber","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.rpth.2026.106929_bib42","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.3390\/ijms21144860","article-title":"The adipokines in cancer cachexia","volume":"21","author":"Mannelli","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rpth.2026.106929_bib43","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2310\/JIM.0b013e3181cf91ca","article-title":"Adipokines in patients with cancer anorexia and cachexia","volume":"58","author":"Smiechowska","year":"2010","journal-title":"J Investig Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:59:02Z","timestamp":1789667942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2475037926035879"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106929","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Distinct changes in plasma protein profiles of cancer patients receiving immune checkpoint inhibitors versus chemotherapy: implications for thrombosis risk and adverse outcomes","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106929"}}